Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20843152 | 0.93 | KDM4E (0.69) | KDM4EKMT2AMEN1CHRM4CHKA | |
| SCHEMBL20257081 | 0.90 | KDM4E (0.65) | KDM4EKMT2AMEN1CHRM4L3MBTL1 | |
| SCHEMBL20257079 | 0.87 | KDM4E (0.62) | KDM4EKMT2AMEN1CHRM4L3MBTL1 | |
| SCHEMBL16130139 | 0.86 | S1PR5 (0.51) | KDM4EKDM1A | |
| SCHEMBL16130110 | 0.86 | S1PR5 (0.51) | KDM4EKDM1A | |
| SCHEMBL17562356 | 0.86 | L3MBTL1 (0.58) | KDM4EKMT2AMEN1CHRM4L3MBTL1 | |
| SCHEMBL17987975 | 0.85 | KDM4E (0.66) | KDM4EKMT2AMEN1CHRM4CHKA | |
| SCHEMBL20257082 | 0.85 | KDM4E (0.62) | KDM4EKMT2AMEN1L3MBTL1CHKA | |
| SCHEMBL17988090 | 0.85 | KDM4E (0.65) | KDM4EKMT2AMEN1CHRM4CHKA | |
| SCHEMBL21101173 | 0.85 | KDM4E (0.56) | KDM4EKMT2AMEN1CHRM4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-9856249-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160068524-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068524-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| WO-2014152229-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTC4S, LTB4R | KDM4E 1707/4885KMT2A 2649/4885MEN1 3813/4885 |
| US-20160068524-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | KDM4E 1707/4885KMT2A 2649/4885MEN1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.